- Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALLKang, Liqing; Ma, Jinfeng; Lou, Xiaoyan; Tang, Xiaowen; Xue, Shengli; Chen, Suning; Qiu, Huiying; Miao, Miao; Han, Yue; Wang, Ying; Sun, Aining; Dai, Haiping; Xu, Yang; Li, Limin; Fan, Shengjin; Qian, Chongsheng; Gong, Wenjie; Xu, Mingzhu; Zhou, Haixia; Yao, Zhen65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell LymphomaTu, Sanfang; Zhou, Lijuan; Huang, Rui; Zhou, Xuan; Yang, Jilong; Li, Meifang; Jin, Bo; Wang, Langqi; Zhuo, Yaqi; Chen, Huifang; Chang, Lung-Ji; Li, Yuhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I StudyHu, Yongxian; Zhang, Jiqin; Zhang, Mingming; Li, Wei; Wu, Wenjun; Cui, Jiazhen; Wei, Guoqing; Du, Bing; Liu, Mingyao; Huang, He64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.
会议论文
Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement
6阅读
